The digoxin affair
Open Access
- 1 February 1974
- journal article
- Published by Oxford University Press (OUP)
- Vol. 50 (580) , 98-102
- https://doi.org/10.1136/pgmj.50.580.98
Abstract
Summary: The cardiac glycosides are potentially dangerous medicines and consistent preparations are necessary. However, presently used tablets of digoxin differ markedly in the fraction of the dose which is absorbed. Measurement of plasma digoxin levels by radioimmunoassay show that absorption from the Lanoxin brand has varied considerably in recent years due to changes in manufacturing technique. Other brands marketed in the U.K. form a wide range of bio-availability. Hazards to the patient are not entirely avoided by brand name prescribing and it is suggested that new pharmacopoeial standards are needed.Keywords
This publication has 8 references indexed in Scilit:
- Therapeutic Non-equivalence of Digoxin Tablets in United Kingdom: Correlation with Tablet Dissolution RateBMJ, 1973
- PARTICLE SIZE AND ABSORPTION OF DIGOXINThe Lancet, 1973
- RATE OF DISSOLUTION OF DIGOXIN TABLETS AS A PREDICTOR OF ABSORPTIONThe Lancet, 1973
- CORRELATION OF DIGOXIN-TABLET DISSOLUTION-RATE WITH BIOLOGICAL AVAILABILITYThe Lancet, 1973
- VARIATION IN THE BIOLOGICAL AVAILABILITY OF DIGOXINThe Lancet, 1972
- Non-cardiac symptoms of digitalis intoxicationAmerican Heart Journal, 1972
- Digitalis IntoxicationNew England Journal of Medicine, 1971
- Plasma Digoxin Concentrations in Patients with Atrial FibrillationBMJ, 1970